Tuesday, December 30, 2014

Suven Life sciences: An Indian multibagger stock, a Value Pick

Stock: Suven Life Sciences
Price when posted: Rs 209 ( 30th Dec 2014 )
Target: 3 bagger by 2017

Suven is a leading Indian Pharma company involved in drug formulation related to the human brain related diseases. They have many patents against their name in this field. They are also a leading player in the CRAMS area. Their plant is also US FDA certified. Their growth rates has been stupendous in the last few years. Have a look at their fundamentals in the below table.


Return on Equity ( 2013 – 14 ) :   68.83 %
Return on Capital employed ( 2013 – 14 ) : 68 %
Sales ( CAGR last 3 years ): 50.37 %          
Net Profit Growth ( CAGR last 3 years ): 143 %
Net Working Capital Cycle (13 – 14 ) : 32 days
Operating cash flow ( last 3 years ): 185 Cr
EPS CAGR Growth ( last 4 years ): 131 %
Current P/E ( TTM ): 20.73
MCap to Sales ( TTM ): 4.2 Times
MCap to Operating Profit ( TTM ): 13.60 Times



Suven stock price is not very cheap now, but great stocks are always not cheap. If you wait it to become cheap, you will only regret later. All of you who have a three year view can buy the stock right away. Suven is listed in the 100 bagger stocks by Motilal Oswal in Dec 2014. Suven is also listed in the Forbes best under a Billion company in Asia.
-----------------------------------------------------------------------------
Disclaimer: It is safe to assume that i have a vested interest in the stock

Feel Free to comment your views on this stock  

Follow me at Twitter: @rvetri

2 comments:

  1. i have lot of conviction here too, good dividend, lots of research, also Motilal oswals

    100 bagger stock

    http://sharemarket-beta.blogspot.in/

    ReplyDelete
  2. ECB forecasters survey sees quicker rise in inflation.
    Capitalstars

    ReplyDelete